Philip Michael Stein

6511973, Jan 28, 2003

Jul 27, 2001

09/916941

Philip D. Stein - Pennington NJ
Yan Shi - Flourtown PA
Stephen P. OConnor - Newtown PA
Chi Li - Randolph NJ

Bristol-Myers Squibb Co. - Princeton NJ

C07D22312

51421203, 51421208, 540524, 540527

Compound of the formula are inhibitors of the enzyme Factor Xa. These compounds are useful as anticoagulants in the treatment of cardiovascular diseases associated with thromboses.

6544981, Apr 8, 2003

Jun 5, 2001

09/874739

Philip D. Stein - Pennington NJ
Stephen P. OConnor - Newtown PA
Yan Shi - Flourtown PA
Chi Li - Randolph NJ

Bristol-Myers Squibb Company - Princeton NJ

C07D40512

51421208, 540526, 540527

Lactam inhibitors are provided which have the structure including pharmaceutically acceptable salts thereof and all stereoisomers thereof, and prodrug esters thereof, wherein n is 1 to 5; and and R , R , R , R , R , R , R , R , R , R , R , R and R are as defined herein. These compounds are inhibitors of Factor Xa and thus are useful as anticoagulants. A method for treating cardiovascular diseases associated with thromboses is also provided.

6555542, Apr 29, 2003

Jan 29, 2002

10/059621

Stephen P. OConnor - Newtown PA
Michael Lawrence - Yardley PA
Yan Shi - Flourtown PA
Philip D. Stein - Pennington NJ

Bristol-Myers Squibb Company - Princeton NJ

A61K 314412

51425309, 514183, 514349, 514345, 514352, 514357, 514408, 514423, 514438, 514445, 514444, 546188, 546207, 546208, 546212, 546223, 546229, 546232, 548566, 548570, 549 74, 549 78, 549 62, 540485, 540596, 540605, 540609

Sulfonamide lactams of the following formula wherein X, R , R , R , R , R , R , R , R , R , R and R are as described herein, are provided which inhibitors of Factor Xa and are useful as anticoagulants in the treatment of cardiovascular diseases associated with thromboses.

6624309, Sep 23, 2003

Sep 25, 2002

10/254398

John Lloyd - Yardley PA
George C. Rovnyak - Hopewell NJ
Philip D. Stein - Pennington NJ
Saleem Ahmad - Wall NJ
Karnail S. Atwal - Newtown PA
Thomas J. Caulfield - Lawrenceville NJ
Michael A. Poss - Lawrenceville NJ

Bristol-Myers Squibb Company - Princeton NJ

C07D 2706

548131, 548247, 548253, 5482676, 5483097, 5483381, 5483751, 548491, 546337, 544264, 544301, 514256, 514261, 514357, 514378, 514381, 514383, 514394, 514399, 514403, 514406, 514415, 514438

Benzoic acid derivatives of the formula where X is oxygen, sulfur, âNH, âNR , âNâCN, âNâOR or âNâNO ; Y is a single bond, âC Câ, or âNH; R is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclo, or (heterocyclo)alkyl; and R is aryl or heterocyclo. The compounds of formula I are useful in the treatment of arrhythmia.

6673824, Jan 6, 2004

Apr 19, 2000

09/552543

Natesan Murugesan - Lawrenceville NJ
John T. Hunt - Princeton NJ
Philip D. Stein - Princeton NJ

Bristol-Myers Squibb Co. - Princeton NJ

A61K 3142

514379, 514380

Compounds of the formula inhibit the activity of endothelin. The symbols are defined as follows: R , R and R are each independently (a) hydrogen, except that R is other than hydrogen; (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z , Z and Z ; (c) halo; (d) hydroxyl; (e) cyano; (f) nitro; (g) âC(O)H or âC(O)R ; (h) âCO H or âCO R ; (i) âSH, âS(O) R , âS(O) âOH, âS(O) âOR , âOâS(O) âR , âOâS(O) OH or âOâS(O) âOR ; (j) âZ âNR R ; or (k) âZ âN(R )âZ âNR R ; and the remaining symbols are as defined in the specification.

6916813, Jul 12, 2005

Dec 10, 2002

10/315818

Karnail S. Atwal - Pennington NJ, US
Gary J. Grover - Stockton NJ, US
Charles Z. Ding - Dallas TX, US
Philip D. Stein - Pennington NJ, US
John Lloyd - Yardley PA, US
Saleem Ahmad - Wall NJ, US
Lawrnce G. Hamann - Cherry Hill NJ, US
David Green - Haverhill MA, US
Francis N. Ferrara - Bedminster NJ, US

Bristol-Myers Squibb Co. - Princeton NJ

A01N043/50
A61K031/415

5142358, 51425401, 514314, 514357, 514361, 514374, 514383, 514394, 514397, 514399, 544139, 544370, 546164, 5462751, 548127, 548204, 5482628, 5483097, 5483147, 5483151, 5483154, 5483365

Compounds having the formula (I), and pharmaceutically acceptable salts thereof, are useful for modulating mitochondrial FFATPase activity and treating ischemic conditions including myocardial infarction, congestive heart failure, and cardiac arrhythmias.

7166586, Jan 23, 2007

Feb 26, 2003

10/374299

Stephen P. O'Connor - Newtown PA, US
Michael Lawrence - Yardley PA, US
Yan Shi - Flourtown PA, US
Philip D. Stein - Pennington NJ, US

Bristol Myers Squibb Co. - Princeton NJ

C07D 41/02
A61K 31/454
A61K 31/445

514183, 514349, 514326, 546207, 546218

Sulfonamide lactams of the following formula.

7659281, Feb 9, 2010

Apr 24, 2007

11/789335

Philip D. Stein - Pennington NJ, US
Steven P. Seitz - Swarthmore PA, US
David J. Carini - Wallingford CT, US
Yan Shi - Flourtown PA, US
Jeffrey A. Robl - Newtown PA, US
Jay A. Markwalder - New London PA, US
Chunhong He - Boothwyn PA, US

Bristol-Myers Squibb Company - Princeton NJ

A01N 43/42
A61K 31/44
C07D 221/18
C07D 221/22

514279, 546 26

Compounds are provided of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia and dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis.